John William Wulf Acquires 81,000 Shares of Agilon Health (NYSE:AGL) Stock

Agilon Health, Inc. (NYSE:AGL) Director John William Wulf purchased 81,000 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was acquired at an average cost of $0.63 per share, for a total transaction of $51,030.00. Following the completion of the acquisition, the director owned 365,857 shares in the company, valued at $230,489.91. This represents a 28.44% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Agilon Health Price Performance

Agilon Health stock opened at $0.84 on Friday. The stock has a market cap of $346.22 million, a P/E ratio of -1.11 and a beta of 0.05. Agilon Health, Inc. has a 1 year low of $0.51 and a 1 year high of $6.08. The firm’s 50 day moving average price is $0.78 and its 200-day moving average price is $1.02.

Agilon Health (NYSE:AGL) last issued its earnings results on Tuesday, November 4th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.09). The company had revenue of $1.44 billion for the quarter, compared to the consensus estimate of $1.43 billion. Agilon Health had a negative return on equity of 75.92% and a negative net margin of 5.24%. As a group, equities analysts expect that Agilon Health, Inc. will post -0.59 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on AGL. Royal Bank Of Canada upgraded Agilon Health from a “hold” rating to a “moderate buy” rating in a research report on Wednesday, December 3rd. Wells Fargo & Company decreased their price objective on Agilon Health from $1.50 to $1.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Barclays cut their target price on shares of Agilon Health from $1.50 to $1.00 and set an “underweight” rating for the company in a report on Thursday, November 6th. Zacks Research raised shares of Agilon Health from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 21st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Agilon Health in a research note on Wednesday, January 21st. Four research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $2.71.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. UBS Group AG lifted its holdings in shares of Agilon Health by 250.7% in the 4th quarter. UBS Group AG now owns 3,395,366 shares of the company’s stock worth $2,339,000 after acquiring an additional 2,427,136 shares during the last quarter. Krilogy Financial LLC purchased a new stake in Agilon Health in the 4th quarter worth about $34,000. Merit Financial Group LLC bought a new stake in Agilon Health in the fourth quarter worth about $35,000. CWM LLC boosted its position in shares of Agilon Health by 4,319.6% during the fourth quarter. CWM LLC now owns 390,958 shares of the company’s stock valued at $269,000 after buying an additional 382,112 shares during the period. Finally, Atwater Malick LLC grew its stake in shares of Agilon Health by 100.0% during the fourth quarter. Atwater Malick LLC now owns 197,576 shares of the company’s stock valued at $136,000 after buying an additional 98,788 shares during the last quarter.

Key Stories Impacting Agilon Health

Here are the key news stories impacting Agilon Health this week:

• Positive Sentiment: Agilon director John William Wulf bought 81,000 AGL shares (avg. $0.63) in November, increasing his stake by ~28%—an insider purchase investors often view as a sign of confidence. Insider Form 4
• Neutral Sentiment: Brokerage consensus remains lukewarm: recent coverage shows an average recommendation of “Hold,” suggesting analysts are cautious but not uniformly bearish. Analyst Consensus
• Negative Sentiment: Bronstein, Gewirtz & Grossman filed/urged investors to act in a class action alleging investor harm against Agilon and certain officers—adds to legal exposure and headline risk. Bronstein, Gewirtz & Grossman filing
• Negative Sentiment: Faruqi & Faruqi says it is investigating claims on behalf of Agilon investors and is soliciting potential class members—more counsel activity increases likelihood of consolidated litigation and potential discovery/settlement costs. Faruqi & Faruqi notice
• Negative Sentiment: Multiple other plaintiff firms (Rosen, Levi & Korsinsky, Bernstein Liebhard, Pomerantz, The Gross Law Firm) have filed or issued shareholder alerts reminding investors of lead‑plaintiff deadlines—this sustained outreach keeps Agilon in the legal headlines and may pressure the stock. Rosen Law Firm notice Levi & Korsinsky notice Bernstein Liebhard notice Pomerantz notice The Gross Law Firm notice

Agilon Health Company Profile

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.